Brodimoprim: therapeutic efficacy and safety in the treatment of bacterial infections.
The clinical efficacy and safety of brodimoprim has been studied by numerous investigators. In the trials reviewed 2291 cases were entered. Of these 2214 were evaluable for efficacy and 2277 for safety. Brodimoprim has been found to exhibit good therapeutic efficacy in upper and lower respiratory tract infections, in bacterial gastroenteritis and in typhoid fever. Response rates in the above indications were reported to be in the range of 85-100% for upper respiratory tract infections, 84-92% for lower respiratory tract infections, 97-100% for bacterial gastroenteritis and 95-100% for enteric fever. In controlled studies these response rates were in the same range as those obtained with standard drugs (ampicillin, amoxicillin, cephalosporins, erythromycin, doxycycline, chloramphenicol). Of the 2277 patients assessable for safety 1429 had received brodimoprim and 848 received a comparative agent. In the brodimoprim group, the overall incidence of clinical adverse events occurring in patients during treatment was 12.7%. The majority of adverse events reported were nausea and vomiting, skin reactions, and CNS reactions. The incidence and pattern of adverse events caused by comparative drugs was similar to those caused by brodimoprim, with the exception of doxycycline which generated fewer clinical adverse events than the other regimens. Brodimoprim in single daily doses may be considered as a highly efficacious and well tolerated antibacterial agent against a broad range of bacterial infections.